Nkarta, Inc.

We are a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf engineered natural killer ("NK") cell therapies. Our primary pipeline program is NKX019, a chimeric antigen receptor-natural killer ("CAR NK") product candidate. NKX019 targets the CD19 antigen and is being developed for the treatment of patients with autoimmune diseases. Our CAR NK platform allows for an on-demand, off-the-shelf approach through scaled manufacturing, aiming to increase patient access. We have developed proprietary technologies to generate a large supply of NK cells, improve their ability to recognize target antigens, and enhance their fitness to support scalable, off-the-shelf administration. NKX019 is allogeneic, meaning it is produced from cells of a donor and can be manufactured in quantity, frozen, and made available for immediate use. This differs from autologous cell therapies, which are made from a patient's own cells and produced individually for each patient. NKX019 is currently undergoing a Phase 1 clinical trial ("Ntrust-1") for lupus nephritis ("LN") and primary membranous nephropathy ("pMN"). It is also in a Phase 1 clinical trial ("Ntrust-2") for systemic sclerosis ("scleroderma"), idiopathic inflammatory myopathy ("myositis"), and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis ("AAV"). Additionally, NKX019 is being studied in an investigator-sponsored trial ("IST") at Columbia University Irving Medical Center for systemic lupus erythematosus ("SLE") and in an IST led by researchers at the University of California, Irvine and the University of Kansas Medical Center for myasthenia gravis ("MG").